Lumigan Shortage: What Providers and Prescribers Need to Know in 2026

For ophthalmologists, optometrists, and other eye care providers managing patients on bimatoprost (Lumigan), access challenges are a real and recurring clinical concern. This guide summarizes the 2026 availability landscape for Lumigan, provides clinically relevant context for patient conversations, and outlines practical pathways for managing access gaps — including bridging therapy, alternative prescribing strategies, and patient assistance resources.

Current Availability Status: 2026 Update

Lumigan (bimatoprost ophthalmic solution) is NOT on the FDA's current drug shortage list as of 2026. National supply is generally intact, with generic bimatoprost 0.03% available from multiple manufacturers and brand Lumigan 0.01% distributed by Allergan (AbbVie). However, providers are increasingly receiving calls from patients unable to fill their prescriptions locally — a pattern driven not by an official shortage but by the structural realities of how ophthalmic drugs move through the supply chain.

Key access barriers in 2026 include:

Brand vs. generic stocking discrepancies: Most community pharmacies prioritize generic bimatoprost 0.03% over brand Lumigan 0.01%. Patients prescribed brand Lumigan by name may encounter extended delays.

Prior authorization burden: Commercial insurance plans frequently require step therapy — first-line use of latanoprost — before approving bimatoprost. PA requirements vary by formulary year.

Mail-order/specialty pharmacy delays: Plans that require specialty or mail-order dispensing add processing time, creating gaps for patients with narrow medication windows.

Clinical Implications: Why Access Gaps Matter for Glaucoma Patients

Bimatoprost lowers IOP by increasing aqueous humor outflow through the trabecular meshwork and uveoscleral pathways. The IOP-lowering effect starts within 4 hours of administration, peaks at 8–12 hours, and lasts approximately 24 hours. Clinical trials show bimatoprost reduces mean IOP by up to 7.5 mmHg from a baseline of ~23.5 mmHg.

When patients miss doses or gap their bimatoprost therapy, IOP can rebound to pretreatment levels within 14 days. For patients with advanced glaucoma or those close to their target IOP, even a brief treatment gap poses meaningful risk of progressive optic nerve damage and irreversible visual field loss. Providers should treat access gaps with the same urgency as a missed dose.

Bridge Therapy and Alternative Prescribing Strategies

When patients cannot access Lumigan, the following evidence-based bridge options are worth considering:

Generic bimatoprost 0.03%: Same active ingredient as Lumigan, more widely available, significantly lower cost. Concentration switch from 0.01% to 0.03% is generally well tolerated; counsel patients on potential increase in hyperemia or eyelash changes with 0.03%.

Latanoprost 0.005%: Most available and affordable prostaglandin analog; IOP reduction of 6–8 mmHg; suitable as a short-term bridge for most glaucoma patients. Generic is universally stocked. Monitor IOP when switching.

Travoprost 0.004% (Travatan Z): BAK-free preservative formulation; useful for patients with ocular surface disease who cannot tolerate benzalkonium chloride.

Timolol 0.5%: Non-selective beta-blocker; appropriate add-on or temporary monotherapy when prostaglandins are unavailable; contraindicated in asthma, COPD, heart block, bradycardia.

Office samples: Contact your Allergan/AbbVie sales representative to maintain a sample supply of Lumigan for patients who face acute access gaps.

Navigating Prior Authorization for Lumigan

Many commercial insurance plans require step therapy documentation before approving brand or generic bimatoprost over latanoprost. To streamline PA submissions:

Document the clinical reason bimatoprost is preferred — e.g., superior IOP reduction needed, patient-specific failure or intolerance of latanoprost, or need for the stronger IOP-lowering effect (bimatoprost reduces IOP by 1–2 mmHg more than latanoprost at some time points).

Note documented latanoprost adverse effects (hyperemia severity, cosmetic changes, or inadequate IOP control) if step therapy has been attempted.

AbbVie's Medical Affairs team can provide clinical literature to support PA appeals for Lumigan.

Patient Assistance Programs Available for Lumigan

For patients who face cost-related access barriers, share the following programs:

AbbVie At Your Service (AYS) co-pay card: Up to $2,640/year in co-pay savings for commercially insured patients (not Medicare/Medicaid). Enroll at savewithays.com.

myAbbVie Assist Patient Assistance Program: Free Lumigan for eligible uninsured or underinsured patients who meet income requirements. Applications via abbvie.com or through the prescribing office.

GoodRx / SingleCare discount coupons: Generic bimatoprost 0.03% as low as $18–$78 at many pharmacies with discount coupons. No insurance needed.

How medfinder Supports Your Patients Between Appointments

When patients contact your office unable to fill their bimatoprost prescription, you can refer them to medfinder. medfinder calls pharmacies on the patient's behalf to identify which ones currently have their medication in stock, then texts results directly to the patient. This reduces the burden on your staff while helping patients get their medication faster.

For a step-by-step patient referral guide, see: How to help your patients find Lumigan in stock: A provider's guide.